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This study evaluates the Health-Related Quality of Life of patients undergoing analogous and 
allogeneic transplantation at three different points in time: before, 30 and 180 days after 
transplantation, along with correlated clinical and socio-demographic data. Two questionnaires 
were used for data collection: the first addressed clinical and socio-demographic data and the 
second was the Functional Assessment Cancer Therapy translated and validated for Brazilian 
Portuguese. The initial sample was composed of 30 patients while 26 were ultimately evaluated 
at the three points. The set of results indicated a positive impact on Health-Related Quality of 
Life six months after transplantation. Despite the fact that there were additional concerns and 
some aspects such as physical and functional aspects were affected 30 days after the procedure, 
the Functional Assessment Cancer Therapy scores obtained six months after HSCT improved 
in all components, reaching levels above those prior to the procedure, especially physical and 
emotional aspects and the relationship with the physician.
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Diseases.
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Avaliação da qualidade de vida relacionada à saúde de pacientes 
submetidos ao transplante de células-tronco hematopoéticas
O objetivo deste estudo longitudinal consistiu em se avaliar a qualidade de vida 
relacionada à saúde de pacientes submetidos ao transplante autólogo e alogênico, 
em três momentos distintos: no pré-transplante, 30 e 180 dias pós-transplante . Para 
a coleta de dados, foram utilizados dois questionários: o primeiro para obtenção de 
dados clínicos e sociodemográficos, e o segundo constituído por uma escala específica, 
o Functional Assessment Cancer Therapy. A amostra inicial foi constituída por 30 
pacientes, sendo 26 avaliados nos três momentos. O conjunto de resultados permitiu 
visualizar impacto positivo da qualidade de vida relacionada à saúde, ao final dos seis 
meses pós-transplante. Apesar de algumas funções se apresentarem mais prejudicadas, 
como a função física, funcional e preocupações adicionais com 30 dias, houve melhora 
nos escores do Functional Assessment Cancer Therapy em todos os componentes, 
chegando-se a alcançar patamares acima dos encontrados na fase do pré-transplante, 
especialmente nos aspectos físicos, emocionais e relacionamento com o médico.
Descritores: Transplante de Células Tronco Hematopoéticas; Qualidade de Vida 
Relacionada à Saúde; Doenças Hematológicas.
Evaluación de calidad de vida relacionada a la salud de pacientes 
sometidos a trasplante de células madre hematopoyéticas
El objetivo de este estudio longitudinal consistió en evaluar la Calidad de Vida 
relacionada a la Salud de pacientes sometidos a trasplante autólogo y alogénico en 
tres momentos distintos: en el pre, 30 y 180 días postrasplante. Para la recolección de 
datos fueron utilizados dos cuestionarios: el primero para obtención de datos clínicos y 
sociodemográficos, y el segundo una escala específica el Functional Assesment Cancer 
Therapy. La muestra inicial fue constituida por 30 pacientes, siendo 26 evaluados en los 
tres momentos. El conjunto de resultados permitió visualizar un impacto positivo de la 
Calidad de Vida relacionada a la salud al final de los seis meses postrasplante, a pesar 
de algunas funciones presentarse más perjudicadas, como la función física, funcional 
y preocupaciones adicionales con 30 días, hubo mejoría en los puntajes del Functional 
Assesment Cancer Therapy en todos los componentes llegando a alcanzar niveles encima 
del pretrasplante, especialmente en los aspectos físicos y emocionales, y en la relación 
con el médico.
Descriptores: Trasplante de Células Madre Hematopoyéticas; Calidad de Vida Relacionada 
a la Salud; Enfermedades Hematológicas.
Introduction
In the past, a cancer diagnosis was a death sentence 
in most cases. Even today it is still associated with pain, 
suffering, fear of becoming dependent on others and 
losing one’s functionality. With the advancement of 
technology that permits the early detection of cancer, the 
possibilities of treatments increasingly broaden such as 
surgeries, radiotherapy, and hormone therapy and also 
the improvement of the antineoplastic and monoclonal 
antibodies therapies and Hematopoietic Stem Cell 
Transplantation (HSCT), the chances of curing cancer 
and improving the survival of patients are increasingly 
greater.
HSCT is used for treating various malignant and 
non-malignant diseases. It consists of intravenously 
infusing stem cells intended to restore bone marrow and 
immune function in patients to enable increased survival 
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free of disease or a complete cure(1-2). The purpose is to 
graft healthy hematopoietic progenitor cells to correct 
a quantitative or qualitative defect of the bone marrow, 
allowing the production of normal blood cells in a process 
called hematopoiesis.
Even though HSCT has been successfully 
implemented there is still a significant risk of physical and 
psychosocial morbidity since secondary comorbidities, 
late side effects and death may occur(1). Morbidity related 
to transplantation is evident in its different phases, 
starting with the period prior to the transplantation 
and conditioning, moving toward post transplantation 
recovery. Cure or complete control of the underlying 
disease may not be followed by health recovery. Hence, 
the health-related quality of life (HRQOL) of survivors 
has emerged as an important field of study.
The patient is the best source of information 
concerning quality of life, which is measured and defined 
according to groups of patients, and may differ among 
the various groups according to the type of disease 
and the therapy secondary side effects, as well as the 
meaning assigned by patients to its benefits or harmful 
effects in the short, medium and long terms. The term 
‘QofL’ encompasses a multidimensional concept that 
incorporates aspects of physical health, performance 
and wellbeing, that is, it is not restricted to symptoms 
related to the disease or its treatment(1).
Even though QofL is a difficult term to be precisely 
defined, it has a meaning common to most people. It 
is composed of broad concepts that influence global 
satisfaction with life, including good health, appropriate 
living conditions, employment, personal and family 
safety, education and leisure. For issues related to health 
care, QofL has been specifically applied to concerns 
whether life is more influenced by health or disease, 
hence the term “health-related quality of life” (3).
Multidimensionality, subjectivity, and bipolarity are 
important components of HRQOL. Even though aspects 
such as weight loss and depression are important, there 
is a growing consensus that HRQOL is composed by a 
number of dimensions that affect one’s life. Seven are 
mentioned(4):
- Physical wellbeing – the experience of physical 
symptoms such as pain, dyspnea, nausea.
- Functional wellbeing – ability to perform regular daily 
activities such as working and leisure.
- Emotional wellbeing – composed of both positive 
affective states (happiness, peace of mind) and negative 
states (sorrow, anxiety).
- Family wellbeing – ability to maintain family 
relationships and communication.
- Social Functioning – ability to participate in and 
appreciate social roles and activities.
- Satisfaction with the treatment – including financial 
concerns
- Sexuality – including concern with body image.
Taking into account this multidimensionality from 
the point of view of health, two things can be grasped: 
one is directly related to health and is called Health-
related Quality of Life (HRQOL) and then a set of factors 
not directly related to it such as non-medical factors, 
constituted of family, friendship, religious believes, 
work, and other life circumstances(5).
The concept of HRQOL can be defined as the 
value one attributes to life, weighted by functional 
deterioration, perceptions and social conditions induced 
by one’s disease, morbidities, treatment and the political 
and economic organization of the care system. The 
individual’s subjectivity is valued in this context(6).
HRQOL is the measure through which the effects of 
a medical condition or its treatment are seen in physical, 
emotional and social wellbeing. The HRQOL evaluation 
requires one’s attention on various dimensions including 
physical concerns (e.g. symptoms), functional ability, 
family and emotional wellbeing, sexuality and social 
functioning. Studies concerning HRQOL, both in the 
general context of a malignant disease and in the specific 
context of HSCT, were centered on clarifying deficits 
in physical, social, emotional wellbeing and wellbeing 
associated with cancer or cancer treatment(7).
Patients undergoing HSCT experience multiple 
symptoms that may negatively affect their HRQOL. 
Family and work relationships may be ruptured due to 
the disease and prolonged treatment. Studies evaluating 
HRQOL of patients undergoing this therapy may be a 
way to evaluate the consequences of HSCT and support 
decision-making at the time of transplantation both for 
patients and the health team.
Despite the various studies addressing the HRQOL 
of individuals undergoing HRCT, there are no conclusive 
results. Some authors agree that there is great harm 
after an HSCT, such as sexual dysfunction, concern with 
unemployment, fatigue, cognitive and psychological 
dysfunction(1,8-9). Others disagree with these results 
showing good physical and psychological recovery after 
HSCT(2,10-13).
Many studies evaluate HRQOL related to HSCT and 
address patients’ adaptation to transplantation over the 
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long term, between one and 10 years after intervention, 
but few address its impact during and immediately after 
hospitalization(2,8-13). Among prospective studies, only a 
few include at least one evaluation prior to the HSCT(12-13). 
Prospective studies are required to evaluate more clearly 
the effect of these treatments related to survival in the 
long run(2). Hence, this study evaluates the HRQOL of 
patients undergoing autologous and allogeneic HSCT in 
the period before intervention and 30 and 180 days after 
intervention.
Method
This is an exploratory descriptive prospective study 
with quantitative approach concerning the HRQOL of 
patients undergoing Allogeneic and Autologous HSCT 
conducted at the Day Hospital and Hospitalization unit of 
an oncological hospital in the interior of São Paulo, Brazil 
cared for between June 2008 to January 2010 after the 
Ethics Research Committee at the facility approved the 
project (Protocol 151/2008).
The sample was composed of patients who met 
the following inclusion criteria: patients undergoing 
allogeneic or autologous HSCT, being 18 years old 
or older at the time of data collection, presenting no 
recurrence of cancer or blood disease resulting from 
HSCT and signing a consent form after doubts were 
clarified.
A script was used to obtain the socio-demographic 
and clinical profile of patients including: age, gender, 
marital status, initial diagnosis, diagnostic data, pre 
or post HSCT and time after HSCT, type of autologous 
or allogeneic HSCT, type of hematopoietic stem cells, 
conditioning, schooling, profession, current occupation, 
origin, the companion’s kinship, time out of home, 
monthly family income, other pathologies, acute or 
chronic graft-versus-host disease, degree and site. Data 
were obtained through an interview and detailed review 
of medical files.
The Functional Assessment of Cancer Therapy 
Bone Marrow Transplantation (FACT-BMT) was used to 
evaluate the patients’ HRQOL. The FACT-BMT is a scale 
specific for patients undergoing HSCT, translated and 
validated for the Brazilian culture(5). The FACT-BMT, 
third version, is composed of 47 questions, 41 of which 
are used to obtain the score, with the remaining six 
presented to provide a synthesis of information, though 
these should not be used to compute the final score. The 
questions are distributed into six domains:
- Physical wellbeing: Composed of seven questions 
that evaluate the presence and intensity of physical 
symptoms resulting from treatment.
- Social/Family wellbeing: Composed of seven questions 
that evaluate the relationship with family and friends 
and changes occurring in these relationships that arise 
from treatment.
- Relationship with the physician: Composed of two 
questions that evaluate trust placed in the physician and 
the relationship with him/her.
- Emotional wellbeing: Composed of six questions that 
evaluate symptoms.
- Functional wellbeing: Composed of seven questions 
that evaluate one’s ability to work and perform daily 
activities and satisfaction with current life conditions.
- Additional concern: Composed of 12 questions that 
evaluate specific questions related to treatment.
FACT-BMT is scored according to each of its 
domains and the sum of the questions’ scores. A Likert 
scale ranges from a score of zero (not at all) to four (vey 
much) for each question. Reverse scores are considered 
for negatively phrased questions. The FACT-BMT final 
score ranges from zero to 164 where higher scores 
represent better quality of life.
The psychometric analysis of the adapted 
version of the FACT-BMT revealed satisfactory internal 
consistency; Cronbach’s alpha ranged from 0.65 to 
0.88. The construct’s validity was analyzed through 
the correlation between the domains of the FACT-BMT 
and SF36 (p<0.001). Significant correlations between 
the FACT-BMT final scores and all the SF36 domains 
(p<0.001) showed this instrument is valid to measure 
quality of life associated with HSCT(5). These results 
supported our choice of the FACT- BMT in this study.
Face-to-face interviews were initiated after the 
study was presented and free and informed consent 
forms were signed, taking around 20 minutes. Socio-
demographic and clinical data were obtained before the 
FACT-BMT was applied. Data were collected at three 
different points in time: prior to HSCT, 30 and 180 days 
after HSCT.
The Statistical Package for Social Sciences (SPSS) 
version 15.0 was used to test the FACT-BMT’s reliability 
and Cronbach’s alpha was applied to test the instrument’s 
internal consistency. The descriptive analysis of data 
(average, median, standard deviation, maximum and 
minimum values) and Fisher’s exact test was applied in 
the STATA SE 11.0 to compare different points. The level 
of significance was fixed at 5% for all tests.
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Results
In relation to the sample’s socio-demographic 
characteristics, the average age in the group was 40 
years old, minimum of 18 and maximum of 60 years 
old, while there were more males (53.3%) than females 
(46.7%). The initial sample was composed of 30 
individuals (both genders). Three of these died in the 
nursing ward and 27 remained in the immediate post 
HSCT phase (30 days after). One of the 27 patients died 
in the immediate post HSCT (37 days after). Hence, 
the evaluated sample in the three points in time was 
composed of 26 individuals.
The profile of the initial sample of 30 patients from 
the clinical point of view was that ten had a diagnosis 
of multiple myeloma, six had acute myeloid leukemia, 
six non-Hodgkin’s Lymphoma, four had Hodgkin’s 
lymphoma, two had chronic leukemia myeloid, one had 
acute lymphoblastic leukemia, and another had severe 
aplastic anemia. Regarding the type of HSCT, 19 patients 
underwent autologous HSCT and 11 the allogeneic HSCT.
Cronbach’s alpha reliability test applied to the 
studied sample resulted in α=0.70, showing that the 
instrument is reliable for the studied sample. The FACT-
BMT average scores were obtained in the three phases 
and then compared among them.
Table 1 – Distribution of average scores obtained in the different aspects of QofL at the different points in time: Prior 
to HSCT and 30 days after HSCT, according to the results obtained from the FACT-BMT
Components
Before 30 Days
p
A SD Min Max A SD Min Max
Physical 18.3 4.7 10.0 27.0 14.7 4.7 5.0 23.0 0.0013*
Socio-family 18.9 4.3 12.0 28.0 18.3 4.0 11.0 26.0 0.2235
Relationship with physician 6.9 1.0 6.0 8.0 7.0 1.0 6.0 8.0 0.7367
Emotional 18.2 3.5 10.0 24.0 17.3 3.6 7.0 23.0 0.1691
Functional 16.5 4.4 10.0 24.0 14.7 2.9 8.0 22.0 0.0085*
Additional concern 32.8 4.7 25.0 43.0 28.9 4.7 20.0 40.0 0.0001*
A=Average; SD=Standard Deviation; *Statistically significant difference
According to data provided in Table 1, there was a 
decrease in the patients’ quality of life on all the scales’ 
components, whereas statistical difference was observed 
in the physical (p=0.0013) and functional (p=0.0085) 
aspects and the additional concern category (p=0.0001) 
30 days after HSCT compared to the time prior to HSCT.
Table 2 – Distribution of average scores obtained in the different aspects of QofL prior to HSCT and 180 day after 
HSCT, according to the results obtained from the FACT-BMT scale
Components
Before 180 Days
p
A SD Min Max A SD Min Max
Physical 18.3 4.7 10.0 27.0 20 4.0 10.0 26.0 0.0321*
Socio-Family 18.9 4.3 12.0 28.0 18.7 4.1 11.0 25.0 0.4706
Relationship with physician 6.9 1.0 6.0 8.0 7.4 0.8 6.0 8.0 0.0348*
Emotional 18.2 3.5 10.0 24.0 19.7 2.6 14.0 23.0 0.0206*
Functional 16.5 4.4 10.0 24.0 17.8 3.0 11.0 22.0 0.0982
Additional concern 32.8 4.7 25.0 43.0 32.7 3.8 24.0 39.0 0.6226
A=Average; SD=Standard Deviation; *Statistically significant difference
According to data provided in Table 2, a slight 
improvement was observed in some components of 
the patients’ quality of life with statistically significant 
differences in the physical (p=0.0321), relationship with 
the physician (p=0.0348) and emotional (p=0.0206) 
components 180 days after HSCT compared to the 
period prior to HSCT.
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Table 3 – distribution of average scores obtained in the different aspects of QofL 30 and 180 days after HSCT 
according to the results obtained in FACT-BMT
Components
30 days 180 days
p
AV SD Min Max A SD Min Max
Physical 14.7 4.7 5.0 23.0 20 4.0 10.0 26.0 0.0000*
Socio-Family 18.3 4.0 11.0 26.0 18.7 4.1 11.0 25.0 0.1634
Relationship with physician 7.0 1.0 6.0 8.0 7.4 0.8 6.0 8.0 0.0672
Emotional 17.3 3.6 7.0 23.0 19.7 2.6 14.0 23.0 0.0026*
Functional 14.7 2.9 8.0 22.0 17.8 3.0 11.0 22.0 0.0003*
Additional concern 28.9 4.7 20.0 40.0 32.7 3.8 24.0 39.0 0.0004*
A=Average; SD=Standard deviation; *Statistically significant difference
According to data provided in Table 3, a statistically 
significant improvement was observed in all the 
participants’ QofL components: Physical (p=0.0000), 
emotional (p=0.0026), functional (p=0.0003) and 
additional concern (p=0.0004), 180 days after HSCT 
compared to 30 days after HSCT.
Discussion
HSCT was successful and resulted in a large 
number of survivors who became free of the disease. 
The big question that emerges for HSCT candidates is 
“how is one’s quality of life after the procedure?” HSCT 
is indicated for malignant or non-malignant pathologies, 
changing the prognosis of patients with diseases that 
not so long ago were considered fatal. However, it is an 
expensive and aggressive procedure with high rates of 
morbidity and mortality, resulting in severe side effects 
and other complications that interfere in the quality of 
life of patients.
The results of this study show that the HRQOL of 
patients is greatly compromised immediately after the 
procedure (30 days after), recovers 180 days after the 
procedure, reaching slightly higher levels compared to 
the period prior to HSCT and corroborate various studies 
reporting that the variable “time” is positively correlated 
with most aspects of HRQOL(10,14-16).
Patients receive high doses of chemotherapy and 
radiation during hospitalization due to HSCT, which 
requires a long period of hospitalization, isolation, 
physical changes and toxicity that threaten life, causing 
anxiety and depression(17).
Harm caused to HRQOL in the first year after HSCT 
is demonstrated in one study(18) addressing 152 patients 
after undergoing HSCT. The content analysis of the 
interviews revealed three affected areas: 1) physical 
problems including fatigue, physical appearance, eating 
problems and physical restrictions; 2) psychological 
problems such as fear about the future, loss of control, 
anxiety and depression; 3) reintegration problems that 
included difficulties resuming social roles, separation 
from home, family and friends and financial hardships.
Other studies(16,19) also show that the HRQOL of 
patients can also significantly suffer in the first year 
after HSCT given potential physical and psychological 
sequelae such as GVHD, fatigue, depression and fear of 
recurrence.
The conclusion is that the variable “time” is related 
to higher scores in HRQOL domains, since patients with 
more time after HSCT present gradual improvement 
of their organic condition, reduced limitations accruing 
from the treatment such as an impossibility to perform 
activities involving physical effort, regular use of 
medications, frequent ambulatory return visits, and 
potential recurrence of the disease(5,16).
Conclusion
A transplanted individual experiences either 
cancer or other hematological diseases that lead to 
transplantation. The aggressive treatment keeps this 
individual distant from home, family, daily activities such 
as work, and under threat of potential complications, in 
addition to fear related to recurrence and death.
The set of results presented permitted us to 
observe a positive impact on HRQOL in patients with 
neoplasia and other hematological diseases undergoing 
HSCT at the end of six months after HSCT. Even though 
some aspects, such as the physical and functional 
aspects, are more compromised 30 days after HSCT and 
patients experience additional concerns, the FACT-BMT 
scores obtained six months after HSCT improved in all 
the components, even reaching higher levels compared 
to the period prior to HSCT, especially in physical and 
emotional terms and in relationship with the physician.
Even though the low number of subjects is considered 
a limitation in this study, its results corroborate those 
in the literature, showing the importance of studies of 
this nature identifying the effect of HSCT on the HRQOL 
of patients undergoing this procedure. Identifying the 
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treatment implications supports decision making of the 
interdisciplinary team and patient as she/he undergoes 
this highly complex procedure, as well as helps the 
planning of care aimed to alleviate symptoms and 
strategies to improve the functionality of these patients.
HRQOL is an important measure of outcomes in 
clinical studies and prospective studies provide follow-
up results with an expectation to improve the patients’ 
HRQOL before and after they undergo HSCT. For that, 
one has also to consider the importance of choosing 
a reliable HRQOL instrument based on the studied 
sample. Such a choice has to be carefully considered to 
detect relevant differences in the life of each patient in 
particular, since data can affect results and conclusions.
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